The answer to this inquiry is “yes” — but maybe “no.” Will confidentiality agreements shield any prior art concerns? Once ...

Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced ...

HonorHealth Research Institute recently treated the first patient in a 50-site international clinical trial that will test a ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

At its April 2025 meeting, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) gave ...

Companies are developing myostatin inhibitors for GLP-1RA-related muscle loss, but some experts question their necessity.

This article is authored by Aditya Sharma, head, Process Solutions, India Region, Merck Life Science, New Delhi.

Annamycin is potentially a highly versatile drug capable of working synergistically with numerous mechanistically different ...

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, ...

The Trump administration’s effort to impose new requirements on Novavax’s COVID-19 vaccine — the nation’s only traditional ...

Like Altimmune, Viking has a promising pipeline candidate targeting MASH, which is also known as nonalcoholic steatohepatitis. The company reported positive phase 2 results for its MASH drug, VK2809, ...

Early cancer biomarkers found in urine can improve screening procedures for the all-too-common prostate cancer.